Last updated on May 2020

Phase 1a Study to Evaluate Immunogenicity of ASV

Brief description of study

This is an open-label Phase 1a First-in-Human Study to determine Safety and Tolerability of ASV AGEN2017 with QS-21 Stimulon Adjuvant as a Single Agent in Subjects With Tumors at Risk of Relapse Undergoing Observation as Standard of Care Following Complete Surgical Resection.

Detailed Study Description

This is a Phase 1a study to evaluate neoantigen vaccine, AutoSynVax (ASV) AGEN2017 in subjects with resected solid tumors, no evidence of disease (NED), and with an estimated life expectancy of 12 months from the time tissue has been submitted for vaccine manufacture. A minimum of 3 subjects will be enrolled to receive every two weeks subcutaneous injection of AGEN2017 + QS-21 adjuvant.

Clinical Study Identifier: NCT03673020

Find a site near you

Start Over